Document is current

Article History

Received: 25 July 2023

Accepted: 15 November 2023

First Online: 14 May 2024

Compliance with ethics guidelines

: <b>Conflicts of Interest</b> Lu Si has received speakers’ honoraria from Merck, Sharp&Dohme, Roche, Novartis, Shanghai Junshi Biosciences, and Oriengene. Jia Jia, Lili Mao, Jing Lin, Wenyu Li, Pei Yuan, Lei Guo, Jie Dai, Caili Li, Xue Bai, Zhongwu Li, Yu Chen, Jun Guo, and Jianming Ying declared no conflicts of interest.

: This study has been conducted in compliance with local Institutional Review Board policies (IRB approval number: 2021YJZ50), and all patients signed informed consent forms prior to sample collection and consented to the publication of related clinical information and data. In addition, the two patients were treated with DV, which was approved by the Pharmacy Administration and Therapeutics Committee of Peking University Hospital for off-label use, and with the informed consent of the patients, the treatment process was in line with clinical diagnosis and treatment norms.